Immunotoxicity verification techniques using human stem cell-derived hepatocytes

摘要

The present invention relates to a method for immunologic hepatotoxicity screening using human stem cell-derived hepatocytes, which comprises administering to a hepatocyte differentiated from human stem cells acetaminophen (APAP) or PPAR gamma agonist (Troglitazone), rosiglitazone (Cytokine) secreted by the hepatocyte, and cytokine, chemokine and lipid mediator secreted by the immune cells were identified. Secondary hepatotoxicity (cytotoxicity) (Immunotoxicity).;